Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30367452 | 1.00 | ESR1 (0.47) | ESR1ALOX5PTGS1PTGS2KDM4E | |
| Hx-1171 SCHEMBL29375871 | 0.93 | ESR1 (0.50) | ESR1ALOX5NR5A1 | |
| Hx-1171 SCHEMBL688955 | 0.93 | ESR1 (0.50) | ESR1ALOX5NR5A1 | |
| SCHEMBL25329980 | 0.91 | PTGS1 (0.45) | ESR1ALOX5PTGS1PTGS2KDM4E | |
| SCHEMBL5588257 | 0.89 | ESR1 (0.47) | ESR1ALOX5PTGS1PTGS2RARB | |
| SCHEMBL30356518 | 0.86 | ESR1 (0.45) | ESR1ALOX5PTGS1PTGS2RARB | |
| SCHEMBL16069600 | 0.86 | ESR1 (0.42) | ESR1ALOX5KDM4EALDH1A1LMNA | |
| SCHEMBL25329401 | 0.84 | ESR1 (0.44) | ESR1ALOX5PTGS1PTGS2TP53 | |
| SCHEMBL24784358 | 0.82 | TSHR (0.41) | ESR1ALOX5KDM4EALDH1A1MAPT | |
| SCHEMBL4449475 | 0.82 | ALDH1A1 (0.42) | ESR1KDM4EALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583813-B2 | Polymerization inhibitors | BASF SE (DE) | 2026-03-24 | — | — | US | disclosed |
| CN-118108589-A | Preparation method of vitamin E intermediate 2,3, 5-trimethylbenzoquinone | 浙江新和成药业有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | BASF SE (DE) | 2023-08-03 | — | — | US | disclosed |
| EP-3287128-A1 | CHRONIC RESPIRATORY DISEASE THERAPEUTIC AGENT AND CARDIAC FIBRILLATION SUPPRESSING COMPOSITION | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-20180049996-A1 | THERAPEUTIC AGENT FOR CHRONIC RESPIRATORY DISEASE AND COMPOSITION FOR INHIBITING CARDIAC FIBROSIS | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2018-02-22 | — | — | US | disclosed |
| EP-2052719-B1 | Curative drug for neurodegenerative diseases | NIPPON HYPOX LAB INC (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2110127-B1 | Hepatic Fibrosis Inhibitor | NIPPON HYPOX LAB INC (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7847132-B2 | Hepatic fibrosis inhibitor | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20100184858-A1 | Hepatic fibrosis inhibitor | BIOTOXTECH CO., LTD (KR) | 2010-07-22 | — | — | US | disclosed |
| US-20100160432-A1 | Curative drug for neurodegenerative diseases | SUGIYAMA SATORU | 2010-06-24 | — | — | US | disclosed |
| US-20090270654-A1 | HEPATIC FIBROSIS INHIBITOR | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-2110127-A1 | Hepatic Fibrosis Inhibitor | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-10-21 | — | — | EP | disclosed |
| EP-2052719-A1 | Curative drug for neurodegenerative diseases | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-04-29 | — | — | EP | disclosed |
| US-20090105339-A1 | Curative drug for neurodegenerative diseases | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184858-A1 | Hepatic fibrosis inhibitor | HDGF, HAVCR2, FABP1 | ESR1 4553/4885ALOX5 1889/4885PTGS1 68/4885 |
| US-20180049996-A1 | THERAPEUTIC AGENT FOR CHRONIC RESPIRATORY DISEASE AND COMPOSITION FOR INHIBITING CARDIAC FIBROSIS | TNNI3, TNNT2, MMP1 | ESR1 4190/4885ALOX5 251/4885PTGS1 26/4885 |
| US-20090105339-A1 | Curative drug for neurodegenerative diseases | HTT, SNCA, NQO1 | ESR1 4628/4885ALOX5 1284/4885PTGS1 986/4885 |
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | RCE1, CABLES1, DPYD | ESR1 3959/4885ALOX5 1518/4885PTGS1 474/4885 |
| US-20100160432-A1 | Curative drug for neurodegenerative diseases | HTT, SNCA, NQO1 | ESR1 4628/4885ALOX5 1284/4885PTGS1 986/4885 |
| US-12583813-B2 | Polymerization inhibitors | PTGS1, PTGER1, POT1 | ESR1 2282/4885ALOX5 560/4885PTGS1 1/4885 |
| US-20090270654-A1 | HEPATIC FIBROSIS INHIBITOR | HDGF, HAVCR2, FABP1 | ESR1 4553/4885ALOX5 1889/4885PTGS1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.